These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33847113)

  • 1. Delivery Strategies for Melittin-Based Cancer Therapy.
    Zhou J; Wan C; Cheng J; Huang H; Lovell JF; Jin H
    ACS Appl Mater Interfaces; 2021 Apr; 13(15):17158-17173. PubMed ID: 33847113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies.
    Yu X; Jia S; Yu S; Chen Y; Zhang C; Chen H; Dai Y
    J Nanobiotechnology; 2023 Nov; 21(1):454. PubMed ID: 38017537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melittin liposomes surface modified with poloxamer 188: in vitro characterization and in vivo evaluation.
    Tian JL; Ke X; Chen Z; Wang CJ; Zhang Y; Zhong TC
    Pharmazie; 2011 May; 66(5):362-7. PubMed ID: 21699070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and preliminary evaluation of poly(amidoamine)-melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics.
    Lavignac N; Lazenby M; Franchini J; Ferruti P; Duncan R
    Int J Pharm; 2005 Aug; 300(1-2):102-12. PubMed ID: 16009513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acid-Activated Melittin for Targeted and Safe Antitumor Therapy.
    Luo L; Wu W; Sun D; Dai HB; Wang Y; Zhong Y; Wang JX; Maruf A; Nurhidayah D; Zhang XJ; Wang Y; Wang GX
    Bioconjug Chem; 2018 Sep; 29(9):2936-2944. PubMed ID: 30148623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGD-modified lipid disks as drug carriers for tumor targeted drug delivery.
    Gao J; Xie C; Zhang M; Wei X; Yan Z; Ren Y; Ying M; Lu W
    Nanoscale; 2016 Apr; 8(13):7209-16. PubMed ID: 26972577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting lipodisks enable selective delivery of anticancer peptides to tumor cells.
    Ahlgren S; Reijmar K; Edwards K
    Nanomedicine; 2017 Oct; 13(7):2325-2328. PubMed ID: 28712916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory activities and biomedical applications of melittin and its recent advances.
    Jafari Z; Sadeghi S; Dehaghi MM; Bigham A; Honarmand S; Tavasoli A; Hoseini MHM; Varma RS
    Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300569. PubMed ID: 38251938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of bee venom and its main constituent melittin for cancer treatment.
    Liu CC; Hao DJ; Zhang Q; An J; Zhao JJ; Chen B; Zhang LL; Yang H
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1113-1130. PubMed ID: 27677623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of Bee Venom Melittin and a Photosensitizer with an Organic-Inorganic Hybrid Nanocarrier for Photodynamic Therapy and Immunotherapy.
    Liu H; Hu Y; Sun Y; Wan C; Zhang Z; Dai X; Lin Z; He Q; Yang Z; Huang P; Xiong Y; Cao J; Chen X; Chen Q; Lovell JF; Xu Z; Jin H; Yang K
    ACS Nano; 2019 Nov; 13(11):12638-12652. PubMed ID: 31625721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melittin-Based Nano-Delivery Systems for Cancer Therapy.
    Wang A; Zheng Y; Zhu W; Yang L; Yang Y; Peng J
    Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of melittin to cancer cells by AS1411 anti-nucleolin aptamer.
    Rajabnejad SH; Mokhtarzadeh A; Abnous K; Taghdisi SM; Ramezani M; Razavi BM
    Drug Dev Ind Pharm; 2018 Jun; 44(6):982-987. PubMed ID: 29325460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.
    Soman NR; Baldwin SL; Hu G; Marsh JN; Lanza GM; Heuser JE; Arbeit JM; Wickline SA; Schlesinger PH
    J Clin Invest; 2009 Sep; 119(9):2830-42. PubMed ID: 19726870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Tumor Effects of Melittin and Its Potential Applications in Clinic.
    Lyu C; Fang F; Li B
    Curr Protein Pept Sci; 2019; 20(3):240-250. PubMed ID: 29895240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bio-nano scale modifications of melittin for improving therapeutic efficacy.
    Akbarzadeh-Khiavi M; Torabi M; Olfati AH; Rahbarnia L; Safary A
    Expert Opin Biol Ther; 2022 Jul; 22(7):895-909. PubMed ID: 35687355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melittin: a lytic peptide with anticancer properties.
    Gajski G; Garaj-Vrhovac V
    Environ Toxicol Pharmacol; 2013 Sep; 36(2):697-705. PubMed ID: 23892471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melittin-incorporated nanomedicines for enhanced cancer immunotherapy.
    Duan X; Zou H; Yang J; Liu S; Xu T; Ding J
    J Control Release; 2024 Nov; 375():285-299. PubMed ID: 39216597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.
    Rady I; Siddiqui IA; Rady M; Mukhtar H
    Cancer Lett; 2017 Aug; 402():16-31. PubMed ID: 28536009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
    Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.